ESMO 2017: Abstracts

Outcome notifications and programme updates

Outcome notifications for Abstracts, Intent to submit LBAs and Trials in Progress will be sent to the submitter and presenter by mid-July.
Accepted Abstract and Trial in Progress titles will be available online 48hrs after outcome notification.
Late Breaking Abstract titles will be available from early August.

Abstract submission closed on
Wednesday 10 May at 21:00 CEST (Central European Summer Time)

Abstract submission deadlines

Deadline Date and time
Abstracts
Intent to submit LBA
Trial in Progress 
Closed
Final Late-breaking abstracts (LBA)   Final submission deadline 19 July 2017, 21:00 CEST (Central European Summer Time)

Please ensure that you have read the ESMO 2017 abstract regulations

Late-breaking abstracts (LBA)

Late-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes.  
Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 10 May 2017 will be considered for late-breaking status.

A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline.

Submitters of preliminary versions receiving approval to proceed must submit the final LBA by 19 July 2017, 21:00 CEST (Central European Summer Time)

The final late-breaking abstract deadline of 19 July 2017 is under no circumstances to be considered as an extension of the general submission deadline.

Presentation outcome for accepted abstracts

The Madrid 2017 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

  • Presidential Symposium – Oral presentations by authors of the very best abstracts containing cutting-edge and significant clinical practice-changing studies, followed by expert discussion and perspectives.
  • Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
  • Poster Discussion – Presentation and analysis by an invited speaker highlighting important findings within a disease type or about a common theme plus interactive audience discussion.
  • Poster – Display sessions for review, discussion and questions. Rotated by category, posters will be displayed for one day of the Congress and the presenting authors must be available for Q&A for one hour to represent their work.

All accepted abstracts will be published in the Madrid 2017 Abstract Book.

Publication schedule for accepted abstracts

Abstracts accepted for presentation at ESMO 2017 as Proffered Paper (oral presentation), Poster Discussion and Poster will be published online on the ESMO website at 00:05 CEST on Thursday, 31 August 2017.

Late-breaking abstracts and abstracts selected for the Press Programme will be made public at 00:05 CEST (local Swiss time) on the day of the official Congress session during which they are presented.